Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 50,000 Shares of Company Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $4.84, for a total value of $242,000.00. Following the sale, the director directly owned 6,108,287 shares of the company’s stock, valued at $29,564,109.08. This represents a 0.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.34, for a total transaction of $100,200.00.
• On Tuesday, August 4th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.25, for a total transaction of $97,500.00.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX traded down $0.36 during mid-day trading on Wednesday, reaching $4.27. 40,600,630 shares of the company’s stock were exchanged, compared to its average volume of 19,026,078. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. The business’s fifty day simple moving average is $3.50 and its two-hundred day simple moving average is $3.37. The firm has a market capitalization of $2.29 billion, a PE ratio of -4.11 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The business had revenue of $7.67 million during the quarter, compared to the consensus estimate of $10.97 million. During the same period in the prior year, the firm earned ($0.41) EPS. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RXRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Morgan Stanley set a $5.30 target price on Recursion Pharmaceuticals in a research report on Monday, August 17th. Finally, Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.06.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in RXRX. MCF Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth approximately $27,000. Fund Advisors of America Inc FL acquired a new position in Recursion Pharmaceuticals during the second quarter valued at approximately $45,000. Integral Investment Advisors Inc. bought a new stake in Recursion Pharmaceuticals during the first quarter worth $39,000. MQS Management LLC bought a new stake in Recursion Pharmaceuticals during the first quarter worth $41,000. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 51.5% in the 1st quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock valued at $47,000 after purchasing an additional 5,156 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.